Cargando…

Clinical Markers of Crohn’s Disease Severity and Their Association With Opiate Use

BACKGROUND: The safety of opiate use for patients with Crohn’s disease (CD) has long been a concern. The recent Crohn’s therapy, resource, evaluation, and assessment tool (TREAT) registry update has added to these concerns by demonstrating an association of opiate use with an increased risk of infec...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheung, Mary, Khan, Sundas, Akerman, Meredith, Hung, Chun Kit, Vennard, Kaitlyn, Hristis, Nicholas, Sultan, Keith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4217751/
https://www.ncbi.nlm.nih.gov/pubmed/25368699
http://dx.doi.org/10.14740/jocmr1969w
_version_ 1782342439724384256
author Cheung, Mary
Khan, Sundas
Akerman, Meredith
Hung, Chun Kit
Vennard, Kaitlyn
Hristis, Nicholas
Sultan, Keith
author_facet Cheung, Mary
Khan, Sundas
Akerman, Meredith
Hung, Chun Kit
Vennard, Kaitlyn
Hristis, Nicholas
Sultan, Keith
author_sort Cheung, Mary
collection PubMed
description BACKGROUND: The safety of opiate use for patients with Crohn’s disease (CD) has long been a concern. The recent Crohn’s therapy, resource, evaluation, and assessment tool (TREAT) registry update has added to these concerns by demonstrating an association of opiate use with an increased risk of infection and death in CD. While the association is clear, the relationship of opiates to these negative outcomes is not. It is unknown whether opiates are a contributing factor to these negative outcomes or if their use is merely a marker of more severe disease. We hypothesized that opiate use is not harmful in CD but is a marker of disease severity and would be associated with commonly accepted clinical markers of severe CD such as early age at CD onset, disease duration, small intestinal involvement, a history of fistula or stricture, and lower quality of life (QOL) scores. METHODS: Data on CD history including pain medication usage were obtained from an interviewer directed survey of patients admitted to two tertiary care hospitals over a 2-year period. CD as the primary admitting diagnosis was not required. Active opiate use was defined by usage within the past month prior to admission. RESULTS: A total of 133 patients were approached to participate, of whom 108 consented to the survey, and 51 were active opiate users. Opiate using CD patients were more commonly smokers (22% vs. 3.45%, P < 0.010), had fistulas (40% vs. 22.4%, P < 0.048) and had a poorer quality of life score by short form inflammatory bowel disease questionnaire (mean 3.80 vs. 4.34, P < 0.036) than non-opiate users. No difference was found between opiate users and non-users for age of diagnosis, disease duration, or a history of strictures. CONCLUSIONS: The study findings demonstrate that opiate use in CD is associated with markers of disease severity including fistulas, smoking, and lower QOL scores. The findings suggest that opiates may not be directly harmful to patients with CD, but may merely be another marker of disease severity. However, given opiates unproven benefits for long term CD pain control and risk of dependence, caution should still be exercised in their use.
format Online
Article
Text
id pubmed-4217751
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-42177512014-11-03 Clinical Markers of Crohn’s Disease Severity and Their Association With Opiate Use Cheung, Mary Khan, Sundas Akerman, Meredith Hung, Chun Kit Vennard, Kaitlyn Hristis, Nicholas Sultan, Keith J Clin Med Res Original Article BACKGROUND: The safety of opiate use for patients with Crohn’s disease (CD) has long been a concern. The recent Crohn’s therapy, resource, evaluation, and assessment tool (TREAT) registry update has added to these concerns by demonstrating an association of opiate use with an increased risk of infection and death in CD. While the association is clear, the relationship of opiates to these negative outcomes is not. It is unknown whether opiates are a contributing factor to these negative outcomes or if their use is merely a marker of more severe disease. We hypothesized that opiate use is not harmful in CD but is a marker of disease severity and would be associated with commonly accepted clinical markers of severe CD such as early age at CD onset, disease duration, small intestinal involvement, a history of fistula or stricture, and lower quality of life (QOL) scores. METHODS: Data on CD history including pain medication usage were obtained from an interviewer directed survey of patients admitted to two tertiary care hospitals over a 2-year period. CD as the primary admitting diagnosis was not required. Active opiate use was defined by usage within the past month prior to admission. RESULTS: A total of 133 patients were approached to participate, of whom 108 consented to the survey, and 51 were active opiate users. Opiate using CD patients were more commonly smokers (22% vs. 3.45%, P < 0.010), had fistulas (40% vs. 22.4%, P < 0.048) and had a poorer quality of life score by short form inflammatory bowel disease questionnaire (mean 3.80 vs. 4.34, P < 0.036) than non-opiate users. No difference was found between opiate users and non-users for age of diagnosis, disease duration, or a history of strictures. CONCLUSIONS: The study findings demonstrate that opiate use in CD is associated with markers of disease severity including fistulas, smoking, and lower QOL scores. The findings suggest that opiates may not be directly harmful to patients with CD, but may merely be another marker of disease severity. However, given opiates unproven benefits for long term CD pain control and risk of dependence, caution should still be exercised in their use. Elmer Press 2015-01 2014-10-16 /pmc/articles/PMC4217751/ /pubmed/25368699 http://dx.doi.org/10.14740/jocmr1969w Text en Copyright 2015, Cheung et al. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Cheung, Mary
Khan, Sundas
Akerman, Meredith
Hung, Chun Kit
Vennard, Kaitlyn
Hristis, Nicholas
Sultan, Keith
Clinical Markers of Crohn’s Disease Severity and Their Association With Opiate Use
title Clinical Markers of Crohn’s Disease Severity and Their Association With Opiate Use
title_full Clinical Markers of Crohn’s Disease Severity and Their Association With Opiate Use
title_fullStr Clinical Markers of Crohn’s Disease Severity and Their Association With Opiate Use
title_full_unstemmed Clinical Markers of Crohn’s Disease Severity and Their Association With Opiate Use
title_short Clinical Markers of Crohn’s Disease Severity and Their Association With Opiate Use
title_sort clinical markers of crohn’s disease severity and their association with opiate use
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4217751/
https://www.ncbi.nlm.nih.gov/pubmed/25368699
http://dx.doi.org/10.14740/jocmr1969w
work_keys_str_mv AT cheungmary clinicalmarkersofcrohnsdiseaseseverityandtheirassociationwithopiateuse
AT khansundas clinicalmarkersofcrohnsdiseaseseverityandtheirassociationwithopiateuse
AT akermanmeredith clinicalmarkersofcrohnsdiseaseseverityandtheirassociationwithopiateuse
AT hungchunkit clinicalmarkersofcrohnsdiseaseseverityandtheirassociationwithopiateuse
AT vennardkaitlyn clinicalmarkersofcrohnsdiseaseseverityandtheirassociationwithopiateuse
AT hristisnicholas clinicalmarkersofcrohnsdiseaseseverityandtheirassociationwithopiateuse
AT sultankeith clinicalmarkersofcrohnsdiseaseseverityandtheirassociationwithopiateuse